Increased serum tumour necrosis factor-α in hidradenitis suppurativa patients: Is there a basis for treatment with anti-tumour necrosis factor-α agents?

Acta Dermato-Venereologica

Volumn 89, Issue 6, 2009, Pages 601-603

  Matusiak, Łukasz ^a   Bieniek, Andrzej ^a   Szepietowski, Jacek C ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Acne inversa; Adalimumab; Etanercept; Hidradenitis suppurativa; Infliximab; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPPURATIVE HIDRADENITIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 71949126504     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0749     Document Type: Article

References (29)

1. Sotiriou E, Apalla Z, Ioannidos D. Etanercept for the treatment of hidradenitis suppurativa. Acta Derm Venereol 2009; 89: 82-83.
2. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813.
3. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623. (Pubitemid 46400178)
4. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561.
5. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 2004; 5: 1767-1770.
6. Fernández-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007; 215: 41-44.
7. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
8. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-1049.
9. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 155: 1105-1107. (Pubitemid 44564546)
10. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-729. (Pubitemid 43374099)
11. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572. (Pubitemid 351239170)
12. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-573.
13. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006; 142: 1110-1112.
14. Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. J Drugs Dermatol 2009; 8: 181-183.
15. Sotiriou E, Apalla Z, Vakirlis E, Ioannides D. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol 2009; 19: 180-181.
16. Hurley H, editor. Dermatologic surgery, principles and practice. New York: Marcel Dekker, 1989.
17. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279. (Pubitemid 41577417)
18. Chodorowska G. Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol 1998; 10: 147-151. (Pubitemid 28137576)
19. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118. (Pubitemid 28045966)
20. Koca SS, Karaca I, Yavuzkir MF, Daǧli N, Ozgen M, Ustündaǧ B, et al. Insulin resistance is related with oxidative stress in systemic lupus erythematosus. Anadolu Kardiyol Derg 2009; 9: 23-28.
21. Lesiak A, Sysa-Jedrzejowska A, Narbutt J, Lukamowicz J, Robak E, Wozniacka A. Proinflammatory cytokines in inactive lupus erythematosus patients. Przegl Lek 2005; 62: 838-842.
22. Ameglio F, D'Auria L, Cordiali-Fei P, Mussi A, Valenzano L, D'Agosto G, et al. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents 1997; 11: 148-153. (Pubitemid 28161874)
23. Erdem MT, Gulec AI, Kiziltunc A, Yildirim A, Atasoy M. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology 2003; 207: 367-370. (Pubitemid 37505784)
24. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007; 156: 51-56. (Pubitemid 44924144)
25. Dvorak VC, Root RK, MacGregor RR. Host-defense mechanisms in hidradenitis suppurativa. Arch Dermatol 1977; 113: 450-453.
26. Lapins J, Asman B, Gustafsson A, Bergström K, Emtestam L. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 2001; 81: 96-99. (Pubitemid 32662147)
27. West MA, Koons A. Endotoxin tolerance in sepsis: concentration-dependent augmentation or inhibition of LPS-stimulated macrophage TNF secretion by LPS pretreatment. J Trauma 2008; 65: 893-898.
28. Korobowicz A. Biologia czynnika martwicy nowotworów typu alfa (TNF α). [Biology of tumor necrosis factor type alpha (TNF-alpha).] Pol Merkur Lekarski 2006; 21: 358-361 (in Polish).
29. Haslund P, Lee RA, Jemec GBE. Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-α Inhibitors. Acta Derm Venereol 2009; 89: 595-600.